Charles Russell Speechlys advises Berkshire Hathaway subsidiary Shaw Industries on acquisition of STS
Charles Russell Speechlys were pleased to advise Shaw Industries Group, Inc. (Shaw) on the acquisition of Scotland-based carpet tile manufacturer Sanquhar Tile Services (STS).
Shaw is the largest carpet tile manufacturer in North America and the acquisition expands its carpet tile footprint to meet the needs of its global customers, complementing its carpet tile manufacturing facilities in the USA and China.
The financial terms of the transaction were not disclosed.
Headquartered in Dalton, Georgia, Shaw has annual revenues of almost $6 billion and is a wholly owned subsidiary of Berkshire Hathaway, Inc. The company employs 22,000 associates with offices; R&D, manufacturing, warehousing and distribution locations; product showrooms and/or salespeople throughout the US, as well as Australia, Belgium, Brazil, Canada, Chile, China, France, India, Mexico, Singapore, United Arab Emirates and the United Kingdom.
Matthew Moore, Senior Counsel at Shaw Industries, commented “As usual, Daniel and the entire team at Charles Russell Speechlys provided excellent counsel to our team throughout this transaction. We are excited about the future of our European business, and pleased we have such a skilled legal partner with Charles Russell Speechlys”.
Daniel Rosenberg, Corporate Partner at Charles Russell Speechlys, said “We were delighted to guide this important and longstanding client through this first major European transaction and look forward to working with them as they expand their footprint in Europe”.
The Charles Russell Speechlys team was led by Daniel Rosenberg and included Charlie Ring, Alex Stevens and Georgina Harris (Corporate), Tanya Wilkie (Commercial), Elliot Michaelson (Tax), Clare Davis (Employment) and Esther White (Pensions).
For more information, please contact Daniel Rosebenberg on +44 (0)20 7427 6541 or at Daniel.Rosenberg@crsblaw.com.
News & Insights
ECM and Brexit: business as usual?
We consider how ECM could be affected by the UK's impending departure from the EU
Kiadis Pharma secures €20 million debt financing facility from Kreos Capital
Charles Russell Speechlys advises Kreos Capital V Ltd on additional growth capital investment of €20 million in Kiadis Pharma NV